🔎 Trials Near Me

Akèy › Lukemi miyoyid nan faz kwonik › New York

Etid klinik pou Lukemi miyoyid nan faz kwonik nan New York

5 etid pou Lukemi miyoyid nan faz kwonik ap chèche patisipan nan sit nan New York.

Vil nan New York

Tèks ofisyèl etid la (Anglè)

Study of Olverembatinib (HQP1351) in Patients With CML-CP

  • Ascentage Investigative Site #1068, Rochester
  • Ascentage Investigative Site #1053, Shirley
  • Ascentage Investigative Site #1160, Stony Brook
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06423911

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

  • Roswell Park Comprehensive Cancer Center, Buffalo
  • Memorial Sloan Kettering Cancer Center, New York
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT04838041

A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

  • NY Cancer and Blood Specialists, East Setauket
  • SUNY Upstate Medical University, Syracuse
Ap rekriteEtid obsèvasyon
Laj 18 a 100 · Tout sèks · Mizajou Jul 20, 2026 · NCT07091019

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

  • Memorial Sloan Kettering Cancer Center, New York
  • Montefiore Medical Center, The Bronx
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 1, 2026 · NCT05304377

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

  • Memorial Sloan Kettering Cancer Center - Main Campus, New York
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jan 12, 2026 · NCT06163430

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.